Novel lipid-polymer hybrid nanoparticles for siRNA delivery and IGF-1R gene silencing in breast cancer cells

Monirinasab, Hannaneh; Asadi, H.; Rostamizadeh, Kobra; Esmaeilzadeh, Abdolreza; Khodaei, Malihe; Fathi, Mojtaba

doi:10.1016/j.jddst.2018.08.025

Cited by 32 publications

(7 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…As a result of this finding, LPHNPs were shown to be more effective and safer to use. The cells incubated with siRNA-LPHNPs indicated a considerable down-regulation of IGF-1R expression in MCF-7 cells ( P < 0.01) in comparison to control cells [ 221 ].…”

Section: Application Of Lphnps For Treatment Of the Different Carcino...mentioning

confidence: 99%

Lipid polymer hybrid nanoparticles: a custom-tailored next-generation approach for cancer therapeutics

Gajbhiye,

Salve,

Narwade

et al. 2023

Mol Cancer

View full text Add to dashboard Cite

Lipid-based polymeric nanoparticles are the highly popular carrier systems for cancer drug therapy. But presently, detailed investigations have revealed their flaws as drug delivery carriers. Lipid polymer hybrid nanoparticles (LPHNPs) are advanced core–shell nanoconstructs with a polymeric core region enclosed by a lipidic layer, presumed to be derived from both liposomes and polymeric nanounits. This unique concept is of utmost importance as a combinable drug delivery platform in oncology due to its dual structured character. To add advantage and restrict one’s limitation by other, LPHNPs have been designed so to gain number of advantages such as stability, high loading of cargo, increased biocompatibility, rate-limiting controlled release, and elevated drug half-lives as well as therapeutic effectiveness while minimizing their drawbacks. The outer shell, in particular, can be functionalized in a variety of ways with stimuli-responsive moieties and ligands to provide intelligent holding and for active targeting of antineoplastic medicines, transport of genes, and theragnostic. This review comprehensively provides insight into recent substantial advancements in developing strategies for treating various cancer using LPHNPs. The bioactivity assessment factors have also been highlighted with a discussion of LPHNPs future clinical prospects. Graphical Abstract

show abstract

Section: Application Of Lphnps For Treatment Of the Different Carcino...mentioning

confidence: 99%

Lipid polymer hybrid nanoparticles: a custom-tailored next-generation approach for cancer therapeutics

Gajbhiye,

Salve,

Narwade

et al. 2023

Mol Cancer

View full text Add to dashboard Cite

show abstract

“…Silencing HMGA2 expression using siRNA is expected to be an efficient approach to suppress breast cancer cell growth. However, the successful delivery of siRNA into the cytoplasm is the essential problem in using it for reducing gene expression [ 30 ]. Therefore, achieving a suitable delivery system with the potential of enhancing siRNA transfection efficiency can facilitate and exert effective gene silencing.…”

Section: Discussionmentioning

confidence: 99%

Silencing of HMGA2 by siRNA Loaded Methotrexate Functionalized Polyamidoamine Dendrimer for Human Breast Cancer Cell Therapy

Gaballu

Cho

Dehghan

et al. 2021

Genes

View full text Add to dashboard Cite

The transcription factor high mobility group protein A2 (HMGA2) plays an important role in the pathogenesis of some cancers including breast cancer. Polyamidoamine dendrimer generation 4 is a kind of highly branched polymeric nanoparticle with surface charge and highest density peripheral groups that allow ligands or therapeutic agents to attach it, thereby facilitating target delivery. Here, methotrexate (MTX)- modified polyamidoamine dendrimer generation 4 (G4) (G4/MTX) was generated to deliver specific small interface RNA (siRNA) for suppressing HMGA2 expression and the consequent effects on folate receptor (FR) expressing human breast cancer cell lines (MCF-7, MDA-MB-231). We observed that HMGA2 siRNA was electrostatically adsorbed on the surface of the G4/MTX nanocarrier for constructing a G4/MTX-siRNA nano-complex which was verified by changing the final particle size and zeta potential. The release of MTX and siRNA from synthesized nanocomplexes was found in a time- and pH-dependent manner. We know that MTX targets FR. Interestingly, G4/MTX-siRNA demonstrates significant cellular internalization and gene silencing efficacy when compared to the control. Besides, the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay demonstrated selective cell cytotoxicity depending on the folate receptor expressing in a dose-dependent manner. The gene silencing and protein downregulation of HMGA2 by G4/MTX-siRNA was observed and could significantly induce cell apoptosis in MCF-7 and MDA-MB-231 cancer cells compared to the control group. Based on the findings, we suggest that the newly developed G4/MTX-siRNA nano-complex may be a promising strategy to increase apoptosis induction through HMGA2 suppression as a therapeutic target in human breast cancer.

show abstract

“…The results revealed high siRNA encapsulation efficiency (80%) and significantly higher cellular uptake of NPs/siRNA between 2–4 hcompared to the free siRNA and the control. Furthermore, treated cells exhibited significant downregulation and reduced expression of the IGF-1R gene (70%) in comparison to control cells [ 103 ]. In another study, aiming to achieve a synergistic effect through sequential and site-specific delivery, Jiang et al fabricated a nanodepot, encapsulating doxorubicin in the interior, with the outer shell consisting of cross-linked hyaluronic acid entrapping a TNFα-related apoptosis-inducing ligand.…”

Section: Breast Cancer In the Era Of Nanomedicinementioning

confidence: 99%

Organic Nanodelivery Systems as a New Platform in the Management of Breast Cancer: A Comprehensive Review from Preclinical to Clinical Studies

Rafik

Vaidya

MacRobert

et al. 2023

JCM

View full text Add to dashboard Cite

Breast cancer accounts for approximately 25% of cancer cases and 16.5% of cancer deaths in women, and the World Health Organization predicts that the number of new cases will increase by almost 70% over the next two decades, mainly due to an ageing population. Effective diagnostic and treatment strategies are, therefore, urgently required for improving cure rates among patients since current therapeutic modalities have many limitations and side effects. Nanomedicine is evolving as a promising approach for cancer management, including breast cancer, and various types of organic and inorganic nanomaterials have been investigated for their role in breast cancer diagnosis and treatment. Following an overview on breast cancer characteristics and pathogenesis and challenges of the current treatment strategies, the therapeutic potential of biocompatible organic-based nanoparticles such as liposomes and polymeric micelles that have been tested in breast cancer models are reviewed. The efficacies of different drug delivery and targeting strategies are documented, ranging from synthetic to cell-derived nanoformulations together with a summary of the interaction of nanoparticles with externally applied energy such as radiotherapy. The clinical translation of nanoformulations for breast cancer treatment is summarized including those undergoing clinical trials.

show abstract

Novel lipid-polymer hybrid nanoparticles for siRNA delivery and IGF-1R gene silencing in breast cancer cells

Cited by 32 publications

References 40 publications

Lipid polymer hybrid nanoparticles: a custom-tailored next-generation approach for cancer therapeutics

Lipid polymer hybrid nanoparticles: a custom-tailored next-generation approach for cancer therapeutics

Silencing of HMGA2 by siRNA Loaded Methotrexate Functionalized Polyamidoamine Dendrimer for Human Breast Cancer Cell Therapy

Organic Nanodelivery Systems as a New Platform in the Management of Breast Cancer: A Comprehensive Review from Preclinical to Clinical Studies

Contact Info

Product

Resources

About